Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Total Liabilities: 2021-2025

Historic Total Liabilities for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to $145,371.

  • ProQR Therapeutics N.V's Total Liabilities rose 23.88% to $145,371 in Q3 2025 from the same period last year, while for Sep 2025 it was $577,962, marking a year-over-year decrease of 99.63%. This contributed to the annual value of $84.8 million for FY2024, which is 18.71% down from last year.
  • As of Q3 2025, ProQR Therapeutics N.V's Total Liabilities stood at $145,371, which was down 6.63% from $155,686 recorded in Q2 2025.
  • ProQR Therapeutics N.V's 5-year Total Liabilities high stood at $230.4 million for Q3 2021, and its period low was $110,502 during Q1 2021.
  • For the 3-year period, ProQR Therapeutics N.V's Total Liabilities averaged around $61.4 million, with its median value being $159,559 (2025).
  • As far as peak fluctuations go, ProQR Therapeutics N.V's Total Liabilities surged by 193,114.16% in 2022, and later slumped by 99.92% in 2024.
  • Quarterly analysis of 5 years shows ProQR Therapeutics N.V's Total Liabilities stood at $110.2 million in 2021, then fell by 3.14% to $106.8 million in 2022, then decreased by 2.75% to $103.8 million in 2023, then dropped by 18.28% to $84.8 million in 2024, then increased by 23.88% to $145,371 in 2025.
  • Its Total Liabilities was $145,371 in Q3 2025, compared to $155,686 in Q2 2025 and $159,559 in Q1 2025.